XON earnings call for the period ending June 30, 2019.
News & Analysis: Intrexon
The biotech is getting into the cannabinoids business.
A big deal with a medical cannabis company provided a spark for Intrexon.
Investors weren't happy to learn about its worsening cash position.
The company got welcome support from a big money manager.
The company's burning through cash, and that has investors nervous.
Intrexon's potential entry into the cannabis industry generated enthusiasm among investors.
A regulatory filing delay provides an unpleasant surprise to the biotech's shareholders.
The company's collaboration revenue took a big step backward in the first quarter.
Intrexon's shares nosedived today on a worse-than-expected third-quarter earnings release.
As Intrexon's losses mount, investors begin to hit the exits.